Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Alexis Moscoso, Michel J. Grothe, Nicholas J. Ashton, et al.
Brain (2020) Vol. 144, Iss. 1, pp. 325-339
Open Access | Times Cited: 178

Showing 1-25 of 178 citing articles:

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
Nicholas J. Ashton, Tharick A. Pascoal, Thomas K. Karikari, et al.
Acta Neuropathologica (2021) Vol. 141, Iss. 5, pp. 709-724
Open Access | Times Cited: 467
Alzheimer's disease drug development pipeline: 2021
Jeffrey L. Cummings, Garam Lee, Kate Zhong, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 418
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Charlotte E. Teunissen, Inge M.W. Verberk, Elisabeth H. Thijssen, et al.
The Lancet Neurology (2021) Vol. 21, Iss. 1, pp. 66-77
Open Access | Times Cited: 354
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Rik Ossenkoppele, Rik van der Kant, Oskar Hansson
The Lancet Neurology (2022) Vol. 21, Iss. 8, pp. 726-734
Open Access | Times Cited: 279
Performance of plasma phosphorylated tau 181 and 217 in the community
Michelle M. Mielke, Jeffrey L. Dage, Ryan D. Frank, et al.
Nature Medicine (2022) Vol. 28, Iss. 7, pp. 1398-1405
Open Access | Times Cited: 277
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Joel Simrén, Antoine Leuzy, Thomas K. Karikari, et al.
Alzheimer s & Dementia (2021) Vol. 17, Iss. 7, pp. 1145-1156
Open Access | Times Cited: 258
Traumatic Brain Injury and Risk of Neurodegenerative Disorder
Benjamin L. Brett, Raquel C. Gardner, Jonathan P. Godbout, et al.
Biological Psychiatry (2021) Vol. 91, Iss. 5, pp. 498-507
Open Access | Times Cited: 245
Aducanumab: Appropriate Use Recommendations
Joanne Cummings, Paul Aisen, Liana G. Apostolova, et al.
The Journal of Prevention of Alzheimer s Disease (2021), pp. 1-13
Open Access | Times Cited: 226
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Oskar Hansson, Kaj Blennow, Henrik Zetterberg, et al.
Nature Aging (2023) Vol. 3, Iss. 5, pp. 506-519
Open Access | Times Cited: 213
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Thomas K. Karikari, Nicholas J. Ashton, Gunnar Brinkmalm, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 7, pp. 400-418
Closed Access | Times Cited: 211
Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies
Aidong Yuan, Ralph A. Nixon
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 195
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
Michelle M. Mielke, Ryan D. Frank, Jeffrey L. Dage, et al.
JAMA Neurology (2021) Vol. 78, Iss. 9, pp. 1108-1108
Open Access | Times Cited: 169
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease
Pratishtha Chatterjee, Steve Pedrini, Nicholas J. Ashton, et al.
Alzheimer s & Dementia (2021) Vol. 18, Iss. 6, pp. 1141-1154
Open Access | Times Cited: 159
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
Sherif Bayoumy, Inge M.W. Verberk, Ben den Dulk, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 140
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Harald Hampel, Yan Hu, Jeffrey L. Cummings, et al.
Neuron (2023) Vol. 111, Iss. 18, pp. 2781-2799
Open Access | Times Cited: 117
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Kanta Horie, Gemma Salvadó, Nicolas R. Barthélemy, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 1954-1963
Open Access | Times Cited: 116
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
Suzanne E. Schindler, Thomas K. Karikari, Nicholas J. Ashton, et al.
Neurology (2022) Vol. 99, Iss. 3
Open Access | Times Cited: 109
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease
Dallas P. Veitch, Michael W. Weiner, Paul Aisen, et al.
Alzheimer s & Dementia (2021) Vol. 18, Iss. 4, pp. 824-857
Open Access | Times Cited: 108
Designing the next-generation clinical care pathway for Alzheimer’s disease
Harald Hampel, Rhoda Au, Soeren Mattke, et al.
Nature Aging (2022) Vol. 2, Iss. 8, pp. 692-703
Open Access | Times Cited: 107
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Fernándo González‐Ortiz, Przemysław R. Kac, Wagner S. Brum, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 106
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Alexa Pichet Binette, Nicolai Franzmeier, Nicola Spotorno, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 85
Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview
Angelica Varesi, Adelaide Carrara, Vitor Gomes Pires, et al.
Cells (2022) Vol. 11, Iss. 8, pp. 1367-1367
Open Access | Times Cited: 75
Predicting amyloid PET and tau PET stages with plasma biomarkers
Clifford R. Jack, Heather J. Wiste, Alicia Algeciras‐Schimnich, et al.
Brain (2023) Vol. 146, Iss. 5, pp. 2029-2044
Open Access | Times Cited: 75
Plasma Biomarkers of Alzheimer’s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice
Marcos Vasconcelos Pais, Orestes Vicente Forlenza, Breno S. Diniz
Journal of Alzheimer s Disease Reports (2023) Vol. 7, Iss. 1, pp. 355-380
Open Access | Times Cited: 63
The dynamics of plasma biomarkers across the Alzheimer’s continuum
Yu Guo, Xue‐Ning Shen, Hui-Fu Wang, et al.
Alzheimer s Research & Therapy (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 54
Page 1 - Next Page

Scroll to top